BHP (ASX: BHP) today reported results for FY20. BHP’s revenues fell by five percent to $42. Billion, while profits fell four percent to $7.9 billion. As a result, BHP will cut the final dividend to 55 US cents, from 78 for FY19. Despite the decline in results, earnings were perhaps only a slight miss on what was expected by analysts, although it was perhaps a slight miss.
BHP indicated that it would look to sell some of its coal operations. Should BHP divest some of these operations, it would likely provide a big cash boost similar to when it divested some of its US oil assets; some of the proceeds from that sale ended up in investors pockets by way of a special dividend.
Cochlear (ASX: COH) today reported a 6 percent drop in revenues to $1.35 billion, while the company moved to a $238 million loss, down from a $276 million profit in FY19. There was a loss of $4 per share. The company will not pay a final dividend as a result.
The result was driven by a rapid drop in sales in the second half and as a result, the company will not provide guidance for FY21. The revenues reported are perhaps slightly better than expected, but the profits are a definite miss. Emerald Equities views Cochlear as unreasonably expensive, even before today’s result.
However, with its recent capital raise significantly oversubscribed, there’s still likely plenty of investors that are willing to pay current prices for Cochlear shares.
To get earnings results like this every day plus recommendations, research, charting and much more, check out our equity research platform Emerald Equities Research.
Atomo Diagnostics (ASX:AT1) has secured a significant new order for its patented Pascal cassette, with…
The June 2025 quarter CPI data released today were cheered by mortgage holders and share…
AI Gains Ground in Defence Sector As governments increase investment in defence technology, AI-powered tools…
Calix Limited (ASX:CXL) has taken a significant leap forward in developing Australia’s low-emissions steel value…
Online tech retailer Harris Technology (ASX: HT8) has delivered a strong lift in gross product…
In a significant move set to reshape rapid diagnostics in the U.S., ASX-listed Lumos Diagnostics…